Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HTPEP-004
- Development stage
- Preclinical
- Lead developer
- Chengdu Huitai Biomedical
- Modality
- Peptides
01
Overview
HTPEP-004 is a peptide-based therapeutic candidate developed by Chengdu Huitai Biopharmaceutical for the treatment of skin fibrosis. It functions by targeting and inhibiting Transforming Growth Factor-beta 1 (TGF-β1), a potent profibrotic cytokine that plays a central role in the activation of myofibroblasts and the accumulation of extracellular matrix components. By antagonizing TGF-β1 signaling, HTPEP-004 aims to prevent or reverse the pathological scarring and tissue stiffening characteristic of fibrotic skin disorders. The drug is currently in the preclinical stage of development.
02
Targets
CD36 (CD36 antigen)TGFB1 (Transforming growth factor Beta-1 proprotein)
Beyond the preview
Go deeper on HTPEP-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HTPEP-004.